Effect of varying the rate of partitioning of phenanthrene in nonaqueous-phase liquids on biodegradation in soil slurries

A study was conducted to determine the influence of varying the rates of partitioning of phenanthrene from nonaqueous-phase liquids to water on its biodegradation. Partitioning rates from dibutyl phthalate and 2,2,4,4,6,8,8-heptamethylnonane were rapid in slurries of soil or aquifer solids that were shaken and were affected by the identity and volume of the non-aqueous-phase liquid. Concentrations of the surfactant Alfonic 810-60 that increased partitioning inhibited biodegradation. The rates of mass transfer from the phthalate to water were not influenced by the identity of the environmental sample. Although the rate of mass transfer of phenanthrene did not limit its mineralization by microorganisms in the soil or aquifer solids, treatments that increased the rate of partitioning enhanced biodegradation, presumably because the treatment overcame some other factor that limited degradation of the hydrocarbon.Peer Reviewe

Vivienda obrera minera en Cartagena-La Unión

The mining “boom” experienced during the XIX century in Cartagena caused a great demographic increase. Population that needs new housing moves to there in a desperate search of new incomes. New villages rose such as “El Estrecho de San Gines” and “El Beal”, and the building of new houses in old zones such as La Unión was increased drastically. Negligible houses were built with similar characteristics, always constructed with poor materials due to lower incomes. Even in the case of the poorest miners, dwelling in caves very close to the mine, homes knowing as “casas-cueva”. Meanwhile a rich highborn people, the owners of the mines, built new and luxury houses, influenced by the modernist architecture wave that rules in Europe. A deep investigation through every plane in the municipal archive of La Unión made locate old planes possible, these planes together with searches over the remainders that nowadays are able to find confirms the main features of the houses built during the objective epoch

El impacto de las medidas contractuales en la estrategia de emprendimiento y empleo joven: un primer intento de evaluación

Ministerio de Economía y Competitividad DER 2012-3675

La aporofobia: ¿una causa naciente de discriminación?

Junta de Andalucía (Consejería de Economía y Conocimiento) US-1264479Fondo Europeo de Desarrollo Regional US-126447

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial

Bevacizumab; Lung neoplasms; Neoplasm metastasisBevacizumab; Neoplasias pulmonares; Metástasis neoplásicaBevacizumab; Càncer de pulmó; Metàstasi neoplàsicaImportance: Antiangiogenic drug combinations with anti-programmed cell death 1 protein and anti-programmed cell death 1 ligand 1 (PD-L1) agents are a novel treatment option for lung cancer. However, survival remains limited, and the activity of these combinations for tumors with high tumor mutation burden (TMB) is unknown. Objective: To assess the clinical benefits and safety of atezolizumab plus bevacizumab for patients with high-TMB advanced nonsquamous non-small cell lung cancer (NSCLC). Design, setting, and participants: This multicenter, single-arm, open-label, phase 2 nonrandomized controlled trial (Atezolizumab Plus Bevacizumab in First-Line NSCLC Patients [TELMA]) included treatment-naive patients aged 18 years or older with confirmed stage IIIB-IV nonsquamous NSCLC with TMB of 10 or more mutations/megabase and no EGFR, ALK, STK11, MDM2, or ROS1 alterations. From May 2019 through January 2021, patients were assessed at 13 sites in Spain, with follow-up until February 28, 2022. Interventions: Participants were given atezolizumab, 1200 mg, plus bevacizumab, 15 mg/kg, on day 1 of each 21-day cycle. Treatment was continued until documented disease progression, unacceptable toxic effects, patient withdrawal, investigator decision, or death. Main outcomes and measures: The primary end point was 12-month progression-free survival (PFS) rate (according to Response Evaluation Criteria in Solid Tumours, version 1.1 criteria); PFS was defined as the time from enrollment to disease progression or death. Adverse events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Results: A total of 307 patients were assessed for trial eligibility, of whom 266 were ineligible for enrollment. Of the 41 patients enrolled, 3 did not fulfill all inclusion criteria and were excluded. The remaining 38 patients (28 [73.7%] male; mean [SD] age, 63.7 [8.3] years) constituted the per-protocol population. The 12-month PFS rate was 51.3% (95% CI, 34.2%-66.0%), which met the primary end point. The 12-month overall survival (OS) rate was 72.0% (95% CI, 54.1%-83.9%). The median PFS was 13.0 months (95% CI, 7.9-18.0 months), and the median OS was not reached. Of the 38 patients, 16 (42.1%) achieved an objective response and 30 (78.9%) achieved disease control. The median time to response was 2.8 months (IQR, 2.8-3.58 months), with a median duration of response of 11.7 months (range, 3.57-22.4 months; the response was ongoing at cutoff). Of 16 responses, 8 (50.0%) were ongoing. Most adverse events were grade 1 or 2. For atezolizumab, the most common adverse events were fatigue (6 [15.8%]) and pruritus (6 [15.8%]). For bevacizumab, they were hypertension (10 [26.3%]) and proteinuria (4 [10.5%]). Drug discontinuation occurred in 2 patients receiving atezolizumab (5.3%) and 3 patients receiving bevacizumab (7.9%). PD-L1 levels were not associated with response, PFS, or OS. Conclusions and relevance: These findings suggest that atezolizumab with bevacizumab is a potential treatment for high-TMB nonsquamous NSCLC

PREVALENCE OF UNKNOWN DIABETES AND IMPAIRED GLUCOSE TOLERANCE IN PATIENTS WITH IMPAIRED FASTING GLUCOSE

There are many community-based studies on the prevalence of diabetes, impaired glucose tolerance (IGT) and impaired fasting glucose (IFG). However, studies on the prevalence of IGT and diabetes unknown in patients with IFG, by 75-g oral glucose tolerance test (OGTT), are few and small.CIBEROBN is an Instituto de Salud Carlos III initiative. This work has been co-financied by CIBEROBN, Research Grants of the Ministerio de Economía y Competitividad of Spain (Instituto de Salud Carlos III: PI10/00913), and Consejería de Salud de la Junta de Andalucía of Spain (PI-0037/2008 and PI-0112-2013).Peer Reviewe

Turnover time of fluorescent dissolved organic matter in the dark global ocean

Research articleMarine dissolved organic matter (DOM) is one of the largest reservoirs of reduced carbon on Earth. In the dark ocean (4200 m), most of this carbon is refractory DOM. This refractory DOM, largely produced during microbial mineralization of organic matter, includes humic-like substances generated in situ and detectable by fluorescence spectroscopy. Here we show two ubiquitous humic-like fluorophores with turnover times of 435±41 and 610±55 years, which persist significantly longer than the B350 years that the dark global ocean takes to renew. In parallel, decay of a tyrosine-like fluorophore with a turnover time of 379±103 years is also detected. We propose the use of DOM fluorescence to study the cycling of resistant DOM that is preserved at centennial timescales and could represent a mechanism of carbon sequestration (humic-like fraction) and the decaying DOM injected into the dark global ocean, where it decreases at centennial timescales (tyrosine-like fraction).Versión del editor10,015

From bioavailability science to regulation of organic chemicals

The bioavailability of organic chemicals in soil and sediment is an important area of scientific investigation for environmental scientists, although this area of study remains only partially recognized by regulators and industries working in the environmental sector. Regulators have recently started to consider bioavailability within retrospective risk assessment frameworks for organic chemicals; by doing so, realistic decision-making with regard to polluted environments can be achieved, rather than relying on the traditional approach of using total-extractable concentrations. However, implementation remains difficult because scientific developments on bioavailability are not always translated into ready-to-use approaches for regulators. Similarly, bioavailability remains largely unexplored within prospective regulatory frameworks that address the approval and regulation of organic chemicals. This article discusses bioavailability concepts and methods, as well as possible pathways for the implementation of bioavailability into risk assessment and regulation; in addition, this article offers a simple, pragmatic and justifiable approach for use within retrospective and prospective risk assessmen

Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson's Disease: Exploring Prodromal Biomarkers.

The search for experimental models mimicking an early stage of Parkinson's disease (PD) before motor manifestations is fundamental in order to explore early signs and get a better prognosis. Interestingly, our previous studies have indicated that 6-hydroxydopamine (6-OHDA) is a suitable model to induce an early degeneration of the nigrostriatal system without any gross motor impairment. Considering our previous findings, we aim to implement a novel system to monitor rats after intrastriatal injection of 6-OHDA to detect and analyze physiological changes underlying prodromal PD. Twenty male Sprague-Dawley rats were unilaterally injected with 6-OHDA (n = 10) or saline solution (n = 10) into the right striatum and placed in enriched environment cages where the activity was monitored. After 2 weeks, the amphetamine test was performed before the sacrifice. Immunohistochemistry was developed for the morphological evaluation and western blot analysis to assess molecular changes. Home-cage monitoring revealed behavioral changes in response to 6-OHDA administration including significant hyperactivity and hypoactivity during the light and dark phase, respectively, turning out in a change of the circadian timing. A preclinical stage of PD was functionally confirmed with the amphetamine test. Moreover, the loss of tyrosine hydroxylase expression was significantly correlated with the motor results, and 6-OHDA induced early proapoptotic events. Our findings provide evidence for a novel prodromal 6-OHDA model following a customized monitoring system that could give insights to detect non-motor deficits and molecular targets to test neuroprotective/neurorestorative agents